Changes to UC Alternative Retirement Plan (ARP) and 403(b)
Plans will be effective on Oct. 1, 2020
The Investment Election window opened on Monday, Aug. 17, and will close on Sept. 19, 2020. Virtual town hall sessions are scheduled over the next few weeks to be held via WebEx. Participants are encouraged to review materials sent to their home as well as attend a WebEx town hall session. An on-demand, recorded version of the WebEx is also available.
As a reminder, the ARP is an offered alternative to the state retirement system (OPERS/STRS), and the university’s 403(b) is available for supplemental retirement plan savings. Changes to the ARP and the 403(b) include reducing the number of approved vendors in order to reduce plan and investment expenses as well as streamlining investment options so that enrollees can better create diversified investment portfolios and track fees.
For more information, refer to the 2020 ARP and 403(b) Retirement Plan Changes page on the Bearcats Landing intranet.
Questions?
Email the UC Benefits team at benefits@uc.edu.
Related Stories
The subtle changes in hearing you should never ignore
July 24, 2026
It’s easy to dismiss changes in hearing as minor. But as The Washington Post recently reported, these symptoms could also signal a medical emergency that many people don’t recognize — known as sudden sensorineural hearing loss, a rapid decline in hearing that occurs suddenly or over a few days.
UC experts say proper produce washing is key defense against Cyclospora
July 24, 2026
Hamilton County Public Health reports confirmed cases of cyclosporiasis, as concerns persist. Cyclospora is a parasite that can cause a stomach illness lasting days — sometimes even weeks. University of Cincinnati medical experts say it is usually linked to contaminated water or food, often fresh produce.
What are the options for male birth control?
July 24, 2026
Despite major advances in contraception during the past several decades, responsibility for pregnancy prevention falls largely on women. As recently reported in Endocrinology Advisor, a new generation of male contraceptive candidates is advancing into early- and mid-stage clinical trials.